Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-01

Study Completion Date

2025-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

NCT00879944

Psoriasis Atopic Dermatitis

COMPLETED

A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis

NCT02382081

Psoriasis

COMPLETED NA

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

NCT01425138

Psoriasis

COMPLETED

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

NCT02239666

Plaque Psoriasis

COMPLETED

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744

Psoriasis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psoriasis patients to be treated only topically

Fasting blood draw for lipid assessments

Intervention Type OTHER

Fasting blood draw for lipid assessments

Psoriasis patients with moderate-to-severe psoriasis who begin

Fasting blood draw for lipid assessments

Intervention Type OTHER

Fasting blood draw for lipid assessments

Age-, sex- and BMI percentile-matched controls

Fasting blood draw for lipid assessments

Intervention Type OTHER

Fasting blood draw for lipid assessments

Patients being treated with isotretinoin for acne

Fasting blood draw for lipid assessments

Intervention Type OTHER

Fasting blood draw for lipid assessments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fasting blood draw for lipid assessments

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children ages 6-17 years of all races/ethnicities with plaque and/or extensive guttate psoriasis for at least 6 months and on topical or systemic therapy
* Patients in the systemic group can be starting a medication for the first time OR transitioning from another systemic if unresponsive and on that previous treatment for ≤ 3 months.
* Patients may concurrently have psoriatic arthritis if initiation of a systemic medication is warranted by skin severity.
* Children ages 6-17 years of all races/ethnicities with acne being treated with isotretinoin
* Children ages 6-17 years of all races/ethnicities without plaque or guttate psoriasis and history of severe acne or treatment with isotretinoin as controls.

Exclusion Criteria

* Patients less than 6 years of age or 18 years and older
* Patients with congenital heart disease, prior cardiac catheterizations/surgeries, or on cardiac medications in the past two years other than for hypertension (eg, calcium channel-blockers, beta-blockers and vasotropic medications).
* Patients who have other systemic inflammatory diseases (including atopic dermatitis, severe acne, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue diseases and/or other autoimmune diseases).
* Patients who have active infection or malignancy or have suffered from infection requiring oral or parenteral antibiotic in past 2 weeks.
* Patients and parents/caregivers unable to give written informed consent.

Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes